by Patricia Weiss and Ludwig Burger
作者：帕特里夏·韦斯和路德维希·伯格
Ingelheim, Germany, April 16 (Reuters) - Boehringer Ingelheim on Tuesday Overtook Bayer Baygn.de as Germany's Largest Drugmaker When the Unlisted Company Reported a Currency-Adjusted Gain in 2023 Pharmaceutical Sales of 10.3% to 20.8 Billion Euros ($22.11 Billion).
德国英格尔海姆4月16日电（路透社）——勃林格·英格尔海姆周二超越了拜耳 baygn.de 作为德国最大的制药商，这家非上市公司报告称，2023年经汇率调整后的药品销售额增长了10.3％，达到208亿欧元（合221.1亿美元）。
Diversified Rival Bayer Reported in March That 2023 Sales at Its Pharmaceuticals Division Slipped 6% to 18.1 Billion Euros, as Gains From Prostate Cancer Drug Nubeqa and Kidney Drug Kerendia Were Offset by Declines in China.
多元化竞争对手拜耳在3月份报告称，由于前列腺癌药物Nubeqa和肾脏药物Kerendia的收益被中国的下跌所抵消，其制药部门2023年销售额下降了6％，至181亿欧元。
Growth at Boehringer's Pharma Unit, Driven by Diabetes Drug Jardiance and Lung Drug Ofev, Pushed 2023 Group Sales, Also Including Its Animal Health Business, up 9.7% at Constant Currencies to 25.6 Billion Euros.
在糖尿病药物Jardiance和肺部药物Ofev的推动下，勃林格制药部门的增长推动了2023年集团的销售额，包括其动物健康业务，按固定货币计算，增长了9.7％，达到256亿欧元。
Boehringer's Jardiance Group of Products, Managed in a Partnership With Eli Lilly Lly.n, Made 7.4 Billion Euros in Annual Sales, a Currency-Adjusted Surge of 31%. Jardiance, Used to Treat Diabetes, Heart Failure and Chronic Kidney Disease, Competes With Astrazeneca's Azn.l Farxiga.
勃林格旗下的Jardiance产品集团，由礼来公司合作管理 lly.n，年销售额为74亿欧元，经汇率调整后增长了31％。用于治疗糖尿病、心力衰竭和慢性肾脏病的Jardiance与阿斯利康竞争 azn.l Farxiga。
Sales of Pulmonary Fibrosis Drug Ofev Rose a Currency-Adjusted 12.8% to 3.5 Billion Euros, Boehringer Said.
勃林格说，经汇率调整后，肺纤维化药物Ofev的销售额增长了12.8％，达到35亿欧元。
Boehringer Is in a Collaboration With Denmark's Zealand Pharma Zela.co to Develop a Weight Loss Drug That the Partners Hope Can Be Launched in 2027 or 2028, to Compete With Lilly's Recently Launched Obesity Drug Mounjaro.
勃林格正在与丹麦的新西兰制药公司合作 Zela.co 制定减肥计划 毒品 合作伙伴希望能够在2027年或2028年推出，以与礼来最近推出的肥胖药物Mounjaro竞争。
for 2024, Boehringer Said It Expects a Slight Increase in Group Revenues, Adjusted for Currency Swings and One-off Effects.
勃林格表示，经汇率波动和一次性影响调整后，预计2024年的集团收入将略有增加。
($1 = 0.9409 Euros)
($1 = 0.9409 欧元)
(Reporting by Patricia Weiss and Ludwig Burger, Editing by Rachel More)
（帕特里夏·魏斯和路德维希·伯格的报道，雷切尔·莫尔编辑）
((Ludwig.burger@Thomsonreuters.com; +49 30 220133634;))
((Ludwig.burger@Thomsonreuters.com; +49 30 220133634;))